Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Chu, Michael P ^a   Lieffers, Jessica ^a   Ghosh, Sunita ^a   Belch, Andrew R ^a   Chua, Neil S ^a   Fontaine, Amelie ^a   Sangha, Randeep ^a   Turner, A Robert ^a   Baracos, Vickie E ^a   Sawyer, Michael B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DEMOGRAPHY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SARCOPENIA; SKELETAL MUSCLE RADIO DENSITY; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOGRAPHY; SKELETAL MUSCLE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DEMOGRAPHY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLE, SKELETAL; RADIOGRAPHY; TREATMENT OUTCOME;

EID: 84935895395     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127589     Document Type: Article

References (27)

1. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(6):1054-60. doi: 10.1200/JCO.2009.24.9730 PMID: 20085939.
2. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. The lancet oncology. 2008; 9(7):629-35. doi: 10.1016/S1470-2045(08)70153-0 PMID: 18539529.
3. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(8):2920-6. doi: 10.1158/1078-0432.CCR-08-2242 PMID: 19351764.
4. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(12):1539-47. doi: 10.1200/JCO.2012.45.2722 PMID: 23530101.
5. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Annals of surgical oncology. 2011; 18(13):3579-85. doi: 10.1245/s10434-011-1976-9 PMID: 21822551.
6. Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013. doi: 10.1002/cncr.28218 PMID: 23801109.
7. Miljkovic I, Kuipers AL, Kammerer CM, Wang X, Bunker CH, Patrick AL, et al. Markers of inflammation are heritable and associated with subcutaneous and ectopic skeletal muscle adiposity in African ancestry families. Metabolic syndrome and related disorders. 2011; 9(4):319-26. doi: 10.1089/met.2010.0133 PMID: 21501070; PubMed Central PMCID: PMC3142634.
8. Miljkovic I, Zmuda JM. Epidemiology of myosteatosis. Current opinion in clinical nutrition and metabolic care. 2010; 13(3):260-4. doi: 10.1097/MCO.0b013e328337d826 PMID: 20179586; PubMed Central PMCID: PMC2872135.
9. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000; 95(3):783-9. PMID: 10648386.
10. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The lancet oncology. 2008; 9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0 PMID: 18226581.
11. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105(4):1417-23. doi: 10.1182/blood-2004-08-3175 PMID: 15494430.
12. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The lancet oncology. 2011; 12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2 PMID: 21940214.
13. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2 PMID: 23433739.
14. Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012; 119(14):3276-84. doi: 10.1182/blood-2011-09-380949 PMID: 22337718.
15. Riihijarvi S, Taskinen M, Jerkeman M, Leppa S. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. European journal of haematology. 2011; 86(2):124-8. doi: 10.1111/j.1600-0609.2010.01541.x PMID: 20942853.
16. Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012; 97(9):1431-8. doi: 10.3324/haematol.2011.059246 PMID: 22511498; PubMed Central PMCID: PMC3436246.
17. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109(5):1857-61. doi: 10.1182/blood-2006-08-038257 PMID: 17105812.
18. Lanic H, Kraut-Tauzia J, Modzelewski R, Clatot F, Mareschal S, Picquenot JM, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leukemia & lymphoma. 2013. doi: 10.3109/10428194.2013.816421 PMID: 23781925.
19. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. Journal of applied physiology. 2004; 97(6):2333-8. doi: 10.1152/japplphysiol.00744.2004 PMID: 15310748.
20. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2008; 33(5):997-1006. doi: 10.1139/H08-075 PMID: 18923576.
21. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. Journal of applied physiology. 2000; 89(1):104-10. PMID: 10904041.
22. Williams BA, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes. Technical Report Series 2006 June 2006.
23. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(5):579-86. doi: 10.1200/JCO.2006.09.2403 PMID: 17242396.
24. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-65. doi: 10.1182/blood-2003-12-4434 PMID: 15126323.
25. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7 PMID: 21176949.
26. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(27):4555-62. doi: 10.1200/JCO.2008.21.3991 PMID: 19652063.
27. Itchaki G, Gafter-Gvili A, Lahav M, Vidal L, Raanani P, Shpilberg O, et al. Anthracycline-containing regimens for treatment of follicular lymphoma in adults. The Cochrane database of systematic reviews. 2013; 7:CD008909. doi: 10.1002/14651858.CD008909.pub2 PMID: 23832787.